These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16083966)

  • 1. Medications development: successes and challenges.
    Vocci F; Ling W
    Pharmacol Ther; 2005 Oct; 108(1):94-108. PubMed ID: 16083966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication development for addictive disorders: the state of the science.
    Vocci FJ; Acri J; Elkashef A
    Am J Psychiatry; 2005 Aug; 162(8):1432-40. PubMed ID: 16055764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy and other treatments for cocaine abuse and dependence.
    Vocci FJ; Elkashef A
    Curr Opin Psychiatry; 2005 May; 18(3):265-70. PubMed ID: 16639150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addiction pharmacotherapy 2000: new options, new challenges.
    Rawson RA; McCann MJ; Hasson AJ; Ling W
    J Psychoactive Drugs; 2000; 32(4):371-8. PubMed ID: 11210198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
    McCann DJ
    Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of addictions.
    Kreek MJ; LaForge KS; Butelman E
    Nat Rev Drug Discov; 2002 Sep; 1(9):710-26. PubMed ID: 12209151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
    Negus SS
    J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in the pharmacotherapy of cocaine abuse.
    Preti A
    Addict Biol; 2007 Jun; 12(2):133-51. PubMed ID: 17508985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
    Gorodetzky CW; Grudzinskas C
    Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ
    J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview: medications development for the treatment of drug abuse.
    Vocci F; Chiang CN; Cummings L; Hawks R
    NIDA Res Monogr; 1995; 149():4-15. PubMed ID: 8775832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opiate addiction in China: current situation and treatments.
    Tang YL; Zhao D; Zhao C; Cubells JF
    Addiction; 2006 May; 101(5):657-65. PubMed ID: 16669899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
    Heidbreder CA; Hagan JJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):107-18. PubMed ID: 15661634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy treatment in substance-dependent correctional populations: a review.
    Cropsey KL; Villalobos GC; St Clair CL
    Subst Use Misuse; 2005; 40(13-14):1983-99, 2043-8. PubMed ID: 16282089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.